Background/purpose: Extracorporeal membrane oxygenation (ECMO) alters the pharmacokinetics (PK) of vancomycin in neonates; but data on adults is limited. Methods: This is a prospective, matched cohort, single center, pharmacokinetic study. For each adult patient who received vancomycin therapy in the ECMO group (with either centrifugal pump or roller pump), a control patient was matched by age (! 60 years or < 60 years), gender, and creatinine clearance (CL Cr ) in intensive care units. After vancomycin was administered for at least four doses, serial blood samples were drawn at 0.5 hours, 1 hour, 2 hours, 3 hours, 5 hours, 7 hours, 11 hours, 23 hours, 35 hours, and 47 hours post vancomycin infusion according to the dosing intervals. The serum concentration-time profile was fitted to a noncompartment model and a nonlinear mixed effect model to determine the PK parameters. Results: Twenty-two critically ill adults without renal replacement therapy were enrolled. There were no significant differences between the ECMO group and the matched group in demographics, renal function, and PK parameters. However, vancomycin clearance in the roller pump group was significantly lower than that in the matched control (0.83 AE 0.43 mL/min/kg vs. 0.97 AE 0.43 mL/min/kg, p Z 0.002). Conclusion: Vancomycin clearance in patients receiving ECMO with a roller pump was significantly lower than that in the matched cohort. Vancomycin PK parameters in patients on ECMO with a centrifugal pump were comparable to those in the matched control group.
Introduction
Extracorporeal membrane oxygenation (ECMO) was initially used for neonates with respiratory failure, 1 and its use has expanded to cardiac or respiratory failure in adults. 2 Blood stream infection was the most common infection acquired during ECMO therapy. 3 With increased nosocomial bloodstream infections by methicillin-resistant Staphylococcus aureus (MRSA), 4 especially in this patient population, 5 vancomycin is frequently used to prevent or treat MRSA infections in patients receiving ECMO in our medical center. ECMO can be viewed as an artificial heart and lung for respiratory and circulatory support, and can be used for a longer period than traditional cardiopulmonary bypass. Its clinical indications include cardiogenic shock, acute respiratory distress syndrome, organ donation, transplantation, and short-term bridge of operation. ECMO is composed of a blood pump, an oxygenator, a heater, and many other components including a monitor. ECMO circuits probably represent another pharmacokinetic (PK) compartment because they can sequester a significant amount of drug, and therefore increase the volume of distribution (V d ). 6 There are various methods such as venoarterial (VA) and venovenous (VV) modes to cannulate ECMO. VA ECMO is achieved by drawing blood from a vein, such as the jugular vein, passing the blood through the oxygenator, and pumping the blood into the aortic arch. The VV mode is similar to the VA mode, except that the blood is pumped back into a different vein. Because the VA mode lacks pulsatility, renal function is transiently altered. 7 Altered renal function is also found in the VV mode. 8 Dagan et al 9 found that drug disposition was altered because the oxygenator could sequester many medications such as vancomycin. In summary, ECMO may alter PK by decreasing drug elimination, increasing the V d , and sequestering drugs in the ECMO circuits. 6 In patients with normal renal function, the reported vancomycin V d , clearance (CL), and half-life (t 1/2 ) are respectively 0.5e1 L/kg, 0.9e1.45 mL/min/kg, and 5e9 hours. 10e14 However, there is limited data on vancomycin PK in adult patients receiving ECMO. Previous studies on the PK of vancomycin in patients receiving ECMO are mostly limited to neonates, and the results are conflicting. Some studies reported a lower vancomycin CL, a larger V d, and a longer t 1/2 , 15e17 while other studies reported that ECMO did not affect the vancomycin PK. 18 Despite the increasing use of vancomycin in adult patients receiving ECMO, 19 there is only one noncontrolled study that evaluated the effect of ECMO on vancomycin PK in adults. 17 The objective of this matched-cohort study was to determine the influence of ECMO on the PK of vancomycin in adults. Determination of an appropriate dosage regimen was also intended for these patients.
Methods

Patient eligibility
This prospective, matched-cohort study was approved by the research ethics committee of the National Taiwan University Hospital, Taipei, Taiwan. The patients on ECMO who received vancomycin treatment, were at least 18 years old were eligible for the study. The patients who used continuous renal replacement therapy, hemodialysis, plasmapheresis, had acute kidney injury [an increase in serum creatinine (S Cr ) of ! 0.3 mg/dL in 24 hours or a reduction in urine output with an output of < 0.5 mL/kg/h for > 6 hours], or suffered from severe burns over 30e40% of the body surface area were excluded from this study. These patients were recruited after informed consent was obtained from them or their representatives.
For each patient in the ECMO group, a control patient was matched by age (! 60 years or < 60 years), gender, and creatinine clearance (CL Cr 
ECMO apparatus
The ECMO system was predominantly composed of a blood pump, a membrane oxygenator, a heater (ECMO-TEMP Unit, Zimmer Patient Care Division, Dover, OH, USA), arterial and venous cannulas, pump tubing, and other monitors. Two types of blood pumps were used for the ECMO group. One blood pump is the centrifugal pump (Biomedicus Pump Console 550, Medtronic Bio-medicus Inc., Eden Prairie, MN, USA) connected with a hollow fiber microporous membrane oxygenator (CBIV97R, Medtronic Inc., Anaheim, CA, USA), and the other type was a roller pump (Precision blood pump, COBE Cardiovascular, Inc., Arvada, CO, USA) connected with a silicone membrane oxygenator (Avecor I4500, Medtronic Inc., Anaheim, CA, USA). The priming fluid was 850 mL of normal saline for the centrifugal pump and 1500 mL of normal saline plus 500 mL of packed red blood cells (pRBC, 80% hematocrit) for the roller pump. The selection of a blood pump was determined by the physicians.
Clinical protocol
The initial loading dose of vancomycin hydrochloride (Vancocin, Eli Lilly Japan K.K, Seishin Laboratories, Kobe, Japan) for the prevention or treatment of MRSA infections was 15e25 mg/kg. The maintenance dose was determined using the PK dosing method [with an empirical V d Z 0.7 L/ kg, CL Z 0.695*CL Cr (mL/min/kg) þ 0.05, and K Z CL/V d ] to achieve trough levels within 10e20 mg/L. 21 Vancomycin was infused through a central venous catheter over at least 1 hour, and serial blood samples (5e9) were drawn from the radial or brachial artery line according to the dosing intervals, which could be every 6 hours, 8 hours, 12 hours, 24 hours, or 48 hours. The sampling times were 0.5 hours, 1 hour, 2 hours, 3 hours, 7 hours, 11 hours, 23 hours, 35 hours, and 47 hours postinfusion. If the dosing interval was 6 hours or 8 hours, an extra sample was drawn at 5 hours postinfusion.
Vancomycin assay method
The drug concentrations in serum were measured using a fluorescence polarization immunoassay (AxSYM system, Abbott Laboratories, Abbott Park, IL, USA). The sensitivity of the assay (the lowest measurable level) was 2 mg/L, and the coefficients of variation at 7.0 mg/L, 35.0 mg/L, and 75.0 mg/L were all < 5%.
Data collection
Demographic and clinical data were recorded for every patient and included age, sex, height, indications for ECMO, type of blood pump, mode of ECMO, vancomycin maintenance dose, and dosing interval. The body weight, S Cr , total bilirubin, aspartate aminotransferase, and alanine aminotransferase on the sampling day were recorded.
Noncompartmental PK analysis
The PK parameters were analyzed using WinNonlin (WinNonlin professional version 4.1, Pharsight Corporation, St. Louis, MO, USA). The serum vancomycin concentrations for all the patients were fitted to a noncompartment intermittent IV infusion model at steady state. The postinfusion log vancomycin concentration in serum time profiles was analyzed with the linear least-squares regression method to estimate the elimination rate constant (k). The t 1/2 , CL, and volume of distribution at steady state (V ss ) were estimated using the following equations: where AUC 0-t is the area under the serum concentration versus time curve over the dosing interval calculated by the linear trapezoidal rule. The MRT inf is the infinite mean residence time.
After acquiring the individual PK parameters, the principles of superposition 22 to predict the vancomycin serum concentrations of each patient was used. The predicted and true concentrations were used to create individual residual plots to assess the appropriateness for setting the steady state. The CL and V ss were adjusted to achieve an appropriate steady state setting if needed.
Statistical analysis
The demographic and PK data were compared with a twotailed paired t test for continuous data, except PK data between the centrifugal pump group and the roller pump group, which were compared with an independent t test. The Chi-square test was used for binomial data. Simple linear regression analysis was used to test for significant relationships between the PK parameters (CL, V ss , t 1/2 ) and the CL Cr . A p value 0.05 was considered statistically significant. The statistical analysis was performed by SPSS 11.5 (SPSS Inc., Chicago, IL, USA).
Population pharmacokinetic analysis
The population PK analysis was performed using NONMEM (Version VI, NONMEM Project Group, University of California, San Francisco, CA, USA) with G77 FORTRAN compiler. NONMEM runs were executed using Wings for NONMEM (WFN; Version 6.1, University of Auckland, Auckland, New Zealand). Wings for NONMEM was also used for model validation using bootstrap resampling. One-, two-, and three-compartment models with first order elimination were fitted to the data using the first-order conditional method of estimation with interaction. Interindividual variability in the PK parameters was modeled with the use of an exponential error model as follows:
where P j is the predicted PK parameter value for the j th patient. q is the typical value of PK parameter in NONMEM. h (ETA) is the random variable, normally distributed with mean equal to 0 and a variance equal to u 2 . The following residual error models to describe residual variability of the population PK model were tested: Proportional error model:
Additive error model:
Combined model (additive and proportional component):
where C ij is the j th measured observation (plasma concentration) in individual i.Ĉ ij is the j th model predicted value (plasma concentration) in individual i. ε 1ij is the proportional component of the residual, residual error for the j th measurement in individual i, with a mean of 0 and a variance of s 1 2 . ε 2ij is the additive component of the residual, residual error for the j th measurement in individual i, with a mean of 0 and a variance of s 2 2 . During the model-building process, the minimum value of the NONMEM objective function (OFV; -2 times the log of the likelihood of the data) was used to discriminate between different models: the better the model fit the data, the lower the OFV. In terms of OFV, differences were assumed to have a c 2 distribution for nested models. OFV reductions (from basic model to nested model) of 3.83 points, 6.63 points, and 10.83 points correspond to improved fits at p < 0.05, p < 0.01, and p < 0.001 levels. The following covariates were tested for their potential influence on PK parameters: age, sex, body weight, CL Cr , albumin, type of blood pump, and mode of ECMO. The full and final model development including the covariate testing was done using the method of "forward inclusion and stepwise backward elimination". In this study, a decrease in the OFV > 3.84 points (i.e., p < 0.05) and 10.8 points (i.e., p < 0.001) were the criteria used in the forward inclusion and backward exclusion steps, respectively.
In addition, the goodness-of-fit of the different population models for vancomycin plasma concentrations was assessed by visual inspection of the following diagnostic plots: (1) observed concentrations versus individual predicted concentrations; (2) observed concentrations versus predicted concentrations; (3) weighted residuals versus predicted concentrations; and (4) weighted residuals versus time. The stability of the final model was evaluated by bootstrapping method. The median parameter estimates obtained from 200 bootstrap replicates were compared with estimates from original dataset.
By using the final population PK model, a simulation was performed for a 50-year-old patient with a body weight of 70 kg and CL Cr of 80 mL/min/1.73 m 2 . Vancomycin was administered at doses of 500 mg, 750 mg, and 1000 mg as a 1 hour infusion (dosing interval of 6 hours, 8 hours, or 12 hours). The concentrationetime profiles of vancomycin were simulated using 1000 replicates of the subject based on the fixed and random effect parameters of the final model, and the median values were computed for the comparison.
Results
Twenty-four patients were included in this study originally. However, one patient in the ECMO group was excluded because of acute kidney injury, and her matched control was therefore excluded from the final analysis. Twenty-two patients were finally enrolled in the two study groups. There were no significant differences between the two groups in the demographic data such as age, height, weight, S Cr , CL Cr , and albumin (Table 1 ). The diagnoses of the patients in the ECMO group included acute respiratory distress syndrome, heart failure, cardiogenic shock, myocarditis, and coronary artery syndrome. The diagnoses of the patients in the control group included trauma, valvular heart disease, cancer, infective endocarditis, septic shock, myocarditis, intracerebral hemorrhage, and dissecting aortic aneurysm. In the ECMO group, a centrifugal pump was used for seven patients, and a roller pump was used for four patients. The VA, VV, and hybrid VV/VA modes were used in seven patients, three patients, and one patient, respectively. There were three obese patients and two obese patients in the ECMO and the control group, respectively.
Noncompartmental PK analysis
Only two patients had their samples drawn after the third dose. Samples from the other patients were drawn after at least the fourth dose. There were no significant differences in the PK parameters of the ECMO group and the matched control; vancomycin CL, (Table 2) . When stratified by the type of blood pump, there were no significant differences in the S Cr and CL Cr whether a centrifugal pump or roller pump was used ( Table 3) Figure 1 ). A linear relationship between the CL Cr and vancomycin CL in all 22 patients (vancomycin CL Z 0.019 * CL Cr e 0.178, r Z 0.73, R 2 Z 0.53, p < 0.001) was used to establish a dosage regimen for the critically ill patients; where the unit for the vancomycin CL is mL/min/kg. After loading with 15 mg/kg, a maintenance dose to achieve an average steady-state concentration (C av, ss ) of 25 mg/L can be calculated as follows: Centrifugal pump (n Z 7)
Matched control-C (n Z 7)
Roller pump (n Z 4) 
Population pharmacokinetic analysis
A one-compartment model with first-order elimination was found to optimally describe the concentration time course of vancomycin. Exponential and proportional error models were used to describe the intersubject and residual variability, respectively. The final population estimates for PK parameters, such as the vancomycin CL and V ss , are shown in Table 5 . All PK parameters were scaled by body weight and were estimated with reasonable precision (% relative standard error < 35%). The interindividual variability for vancomycin CL and V ss were 38.3% and 21.2%, respectively. The residual variability of the model was 16.3%. In the final covariate model, CL cr were identified as a significant covariate for vancomycin CL. Age was also found to be a significant covariate for V ss . The final model can be represented by the following equations:
The diagnostic plots of the final model are given (Figure 2) . The individual-and population-predicted vancomycin concentrations show good agreement with the observed vancomycin concentrations (Figures 2A and  2B) , demonstrating that the model adequately described the data. The plots of weighted residual versus the population-predicted vancomycin concentrations ( Figure 2C ) or time ( Figure 2D ) do not show any obvious trend. From 200 bootstrap runs, all the runs had a successful minimization and were included in the bootstrap analysis. All model estimates lie within the bootstrapped 95% confidence interval range. The median parameter estimates from the bootstrap datasets were close to those from the original dataset, indicating the population PK model was stable.
The concentrationetime profiles of vancomycin, after multiple doses of 500 mg, 750 mg, and 1000 mg as a 1 hour infusion (dosing interval of 6 hours, 8 hours, or 12 hours), was simulated with the final PK model (Figure 3) . The current vancomycin therapeutic guidelines recommend targeting vancomycin trough concentrations of 10e20 mg/L for patients with complicated infections. In accordance to the above mentioned guide, a dosing regimen of 500 mg repeated every 6 hours, 750 mg repeated every 8 hours, and 1000 mg repeated every 12 hours seems to be optimal for a 50-year-old, 70 kg patient with a CL Cr of 80 mL/min/ 1.73 m 2 .
Discussion
This study is the first prospective, matched cohort study to explore the effect of ECMO on the PK of vancomycin in adults. To the best of our knowledge, it is also the first Figure 1 Vancomycin clearance versus creatinine clearance. In the ECMO group: n Z 11, r Z 0.61, R 2 Z 0.37, y Z 0.017x À0.086, p Z 0.045. In the control group: n Z 11, r Z 0.78, R 2 Z 0.61, y Z 0.019x e 0.185, p Z 0.005. In all patients:
n Z 22, r Z 0.73, R 2 Z 0.53, y Z 0.019x e 0.178, p < 0.001. CL Z clearance; CL cr Z creatinine clearance. study that enrolled patients on ECMO with a centrifugal pump. Vancomycin PK may be altered during ECMO in adult patients due to multiple reasons including priming volume, transfusion and hemodilution, decreasing renal function, and sequestering drugs in the ECMO circuit. 6 The results in our study did not show ECMO to be a significant covariate to impact vancomycin PK when a centrifugal pump was used. CL Cr and age were two significant covariates of vancomycin CL and V ss , respectively. However, vancomycin CL was significantly lower than that in the matched cohort when roller pump was used. The elimination rate constant of vancomycin was significantly lower in the roller pump group than that in the centrifugal pump group.
Prior to our study, there has been only one uncontrolled study conducted by Mulla and Pooboni, 17 which enrolled 18 adult patients and used a population PK method to estimate the vancomycin PK parameters in adults who received ECMO with a roller pump. The study revealed a much lower vancomycin CL but a similar V ss when compared with our study (Table 6 ). Although it concluded that there was a decreased vancomycin CL and increased V ss in patients receiving ECMO, the lack of a control groups limits accurate interpretation of their findings. The kinetic changes might have been due to the patients' critical condition. All the other studies focused on neonates and are difficult to compare with our study. Hoie et al 18 conducted a prospective study of six neonates, and Mulla and Pooboni 17 also enrolled neonates and children. The PK parameters of vancomycin found in these two studies were similar to those found in studies of other neonates not undergoing ECMO.
23,24 Buck 16 conducted a retrospective controlled study of 15 neonates and found that only the t 1/2 was significantly longer in neonates receiving ECMO (Table 6 ). The study by Amaker et al 15 was the only study to reveal a large change in the PK parameters in neonates. This may be explained by higher percentage of extracellular fluid expansion in neonates using ECMO. The addition of priming fluid expanded the extracellular fluid by 36% for a 4-kg neonate and by 6e15% for a 70-kg adult. Because the percentage extracellular fluid expansion is lower in adult, there were no significant difference in k, V ss , and CL in our study (Table 6) .
Sequestration of drugs in the ECMO circuit was considered as a factor in changing the drug disposition. 9 However, the intergroup difference of the V ss was only 0.03 L/kg in our study. This difference was most likely caused by the priming fluid instead of the sequestration of the drugs in the circuit. Shekar et al 25 demonstrated that there was no significant circuit loss of vancomycin. In our study, ECMO was used for many days before the blood sampling, and many drugs, such as albumin, were used concurrently, which might decrease the binding sites on the ECMO circuit and minimize the effect of sequestration.
There was a trend toward a lower vancomycin CL and a longer t 1/2 in patients receiving ECMO in this and other studies. Vancomycin is eliminated predominantly by renal excretion. The nonpulsatile blood flow of the ECMO circuit could increase the sympathetic tone and result in decreased renal perfusion and urine output, which could decrease the elimination of vancomycin and lead to a lower vancomycin CL and a longer t 1/2 . 26 The patients receiving ECMO with a roller pump in our hospital were often more critically ill than those on a centrifugal pump, and the renal function in the roller pump group was worse than that in the centrifugal pump group. This can be the cause of a significantly lower k in the roller pump group. In addition, although not statistically significant, the V ss was larger and the vancomycin CL was lower in the roller pump group. A silicone membrane oxygenator may sequester more drugs than a hollow fiber microporous membrane oxygenator. 27 This is a possible cause of larger V ss in the roller pump group. There is an increasing tendency to use a centrifugal pump that offers several potential benefits over a roller pump, which includes a smaller circuit size to lower circuit prime volumes and a smaller surface area for bloodeprosthetic surface interaction to minimize activation of inflammatory factors. 28 These advantages may also cause PK differences between the two different pump groups. To the best of our knowledge, only our study had enrolled patients receiving centrifugal pump. However, it also implied this study consisted of heterogeneous groups including two different pumps used and three types of cannulation method.
The trough serum concentration is the most accurate and practical method for monitoring vancomycin efficacy and should be maintained at 10e20 mg/L to prevent resistance and maintain efficacy. 29 However, in our study, only 27% (3 in 11) patients in the ECMO group achieved this target. Over 54% trough serum concentration was subtherapeutic and 18.2% exceeded 20 mg/L in the ECMO group. Similar results were seen in the matched control group. Even though a short dosing interval such as every 6 hours was used, > 50% was subtherapeutic. Many dosing nomograms were used empirically to give the vancomycin dose; however, critically ill patients were not enrolled in these studies. 10, 11, 30 This may explain the high percentage of inadequate trough level when using these nomograms. Therefore, a specific dosage regimen for patients on ECMO is required.
Based on the dosing simulation with population PK, in a patient with a CL Cr of 80 mL/min/1.73 m 2 , vancomycin dose of 1000 mg every 12 hours could achieve target trough level (Figure 3) . However, not every critically ill patient has the same renal function. Therefore, a dosing equation: maintenance dose (mg/kg/24 hours) Z 0.684 * CL Cr (mL/ min/1.73 m 2 ) e 6.408] was derived in this study for ECMO group and control group utilizing the correlation between vancomycin CL and CL Cr (r Z 0.73 in all patients). Although this equation is derived from a critically ill population, close monitoring of the vancomycin serum concentration is still recommended because of the moderate correlation. Continuous infusion of vancomycin is a probable solution to maintain concentration within therapeutic range. However, although continuous infusion of vancomycin could achieve target concentration faster and caused less renal toxicity than intermittent infusion, the overall mortality was not significantly different. 31, 32 Further studies are needed to validate the new dosing method and continuous infusion of vancomycin in patients using ECMO.
There are some limitations to our study. Firstly, the small population of our study may not have enough power to detect the true difference between the groups. The difference in the V ss of vancomycin between the groups was too small to be clinically significant. Further studies are needed to prove a meaningful trend of a lower vancomycin CL in patients receiving ECMO. Secondly, the disease status was very different between the two groups. The vancomycin PK may be altered by severe diseases through the effects on renal function. However, this study matched the CL Cr of the two groups to minimize the effect of different disease status. Although CL Cr by measuring 24-hour urine is a gold standard for renal function assessment, it is not a routine practice in our intensive care units. The CG method was used in our study for renal function matching because of the good linear correlation between CL Cr by measuring 24-hour urine and CL Cr estimated by CG method (R 2 Z 0.84). 33 In addition, when CL Cr < 100 mL/min/ 1.73 m 2 , the difference between these two method was 
Conclusion
In patients receiving ECMO with a roller pump, vancomycin clearance is significantly lower than that in the matched group. Vancomycin PK parameters in patients on ECMO with * p < 0.05. C Z centrifugal pump; ECF Z extracellular fluid; NA Z not available; N/S Z normal saline; PRBC Z pack red blood cells; R Z roller pump; V ss Z volume of distribution at steady state. a Based on a 4 kg neonate and a 70 kg adult. ECF of a neonate (4 kg): 1400 mL, plasma of a neonate: 350 mL. ECF of an adult (70 kg): 4000 mL; plasma of an adult: 3500 mL. Expanded volume Z N/S þ RBC*(1-Hct). a centrifugal pump were comparable to those in the matched cohort. There was a higher risk of under dosing in both the ECMO and the matched groups, and close monitoring of serum drug concentration was recommended. Administering vancomycin as a 24-hour continuous infusion, especially in patients with higher CL Cr , needs further investigation.
